Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

EULAR 2023 Insights: From Pathogenesis to Therapy in Sjögren's Syndr…

EULAR 2023 Insights

H. Bootsma

Practical Aspects of Bispecifics in NHL: Supportive Care and Minimiz…

UChicago Medicine

K. Kelly

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

Monia Marchetti

Treatment-Related Quality of Life in MF

Winship Cancer Institute - Emory University

A. Hunter

The Potential Role of ctDNA in Hodgkin Lymphoma Management

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

I. Panovska-Stavridis

Medical Therapy Related Complications in IBD

Cedars Sinai

M. Long

Review and Updates of New and Upcoming Cytopathology Reporting Syste…

Houston Methodist

E. M. Jacobi

High-Grade B-Cell Lymphomas, Not Otherwise Specified: How To Differe…

19th Annual International Ultmann Chicago Lymphoma Symposium

D. Scott

Moffitt Cancer Center Debate: Should NGS Be Reported in All Newly Di…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

B. Shah, H. Saeed

Lymphoblastic Lymphoma: How Effective Are ALL-Regimen Therapy and CH…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

A. Antipova

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz